Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11


DIMming ovarian cancer growth.

Kandala PK, Srivastava SK.

Curr Drug Targets. 2012 Dec;13(14):1869-75. Review.


Inhibition of EGFR-AKT axis results in the suppression of ovarian tumors in vitro and in preclinical mouse model.

Loganathan S, Kandala PK, Gupta P, Srivastava SK.

PLoS One. 2012;7(8):e43577. doi: 10.1371/journal.pone.0043577. Epub 2012 Aug 27.


Diindolylmethane-mediated Gli1 protein suppression induces anoikis in ovarian cancer cells in vitro and blocks tumor formation ability in vivo.

Kandala PK, Srivastava SK.

J Biol Chem. 2012 Aug 17;287(34):28745-54. doi: 10.1074/jbc.M112.351379. Epub 2012 Jul 6.


Blocking epidermal growth factor receptor activation by 3,3'-diindolylmethane suppresses ovarian tumor growth in vitro and in vivo.

Kandala PK, Wright SE, Srivastava SK.

J Pharmacol Exp Ther. 2012 Apr;341(1):24-32. doi: 10.1124/jpet.111.188706. Epub 2011 Dec 28.


The role of K-ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines.

Sahu RP, Batra S, Kandala PK, Brown TL, Srivastava SK.

Cancer Chemother Pharmacol. 2011 Feb;67(2):481-7. doi: 10.1007/s00280-010-1463-1. Epub 2010 Sep 17.


Benzyl isothiocyanate-mediated inhibition of histone deacetylase leads to NF-kappaB turnoff in human pancreatic carcinoma cells.

Batra S, Sahu RP, Kandala PK, Srivastava SK.

Mol Cancer Ther. 2010 Jun;9(6):1596-608. doi: 10.1158/1535-7163.MCT-09-1146. Epub 2010 May 18.


Activation of checkpoint kinase 2 by 3,3'-diindolylmethane is required for causing G2/M cell cycle arrest in human ovarian cancer cells.

Kandala PK, Srivastava SK.

Mol Pharmacol. 2010 Aug;78(2):297-309. doi: 10.1124/mol.110.063750. Epub 2010 May 5.


Structure-toxicity relationship of phenolic analogs as anti-melanoma agents: an enzyme directed prodrug approach.

Vad NM, Kandala PK, Srivastava SK, Moridani MY.

Chem Biol Interact. 2010 Feb 12;183(3):462-71. doi: 10.1016/j.cbi.2009.11.020. Epub 2009 Nov 26.

Supplemental Content

Loading ...
Support Center